Left ventricular noncompaction

Mihaela Rugină1, L.M. Predescu1, Mihaela Sălăgean1, I. M. Coman1,2, Ş. Bubenek-Turconi1,2

Article received on the 7th of April 2013. Article accepted on the 2nd of May 2013.

INTRODUCTION

Left ventricular noncompaction (LVNC) is a cardiomyopathy with genetic determinism, that it is not widely accepted like a distinct cardiomyopathy, still being considered a congenital or acquired morphological characteristic of other different cardiomyopathies1.

In the position statement of the European Society of Cardiology, LVNC is included in the unclassified cardiomyopathies group because it is not clear whether it is a separate cardiomyopathy or merely a morphological trait shared by many phenotypically distinct cardiomyopathies2. The American Heart Association classified LVNC as a primary cardiomyopathy.

The characteristic echocardiographic features in individuals affected by LVNC include a thick, bilayered (compacted and noncompacted) myocardium; prominent ventricular trabeculations; and deep intertrabecular recesses.

EPIDEMIOLOGY

The population prevalence of isolated LVNC is not known, but it is reported in 0.014% -1,3 % of consecutively examined patients. In large pediatric series, LVNC is reported to be the commonest cause of unclassified cardiomyopathies3. In some reports, LVNC is more frequent in men than in women (1,5:1)4. This poor estimation of the LVNC prevalence is partially explained by the non uniform diagnostic criteria used. The prevalence of LVNC has raised because of a better echocardiographic identification.

The various names used to describe the morphologic profile of LVNC include “honeycomb,” “persistent sinusoids,” “spongy myocardium,” “persistent embryonic myocardium,” “hypertrabeculation,” “LVNC,” “LVNC/hypertrabeculation syndrome,” and “noncompaction of the ventricular myocardium”5.

EMBRYOLOGY

Briefly, in the development of the heart, the myocardium has a trabeculated aspect with deep intertrabecular recesses. This stage is encountered before the development of coronary arteries. In the 5 to 8 week of gestation the compaction of the myocardium has place, the intertrabecular recesses becoming the coronary ar-

Abstract: Left ventricular noncompaction (LVNC) is a cardiomyopathy associated with sporadic or familial disease, the latter having an autosomal dominant mode of transmission. Echocardiography is the current gold standard for diagnosis of this entity, but with the risk of over diagnosis and under diagnosis. There are frequent doubtful cases, that need multimodality confirmation (echocardiography and magnetic resonance imaging). The clinical features associated with LVNC vary from asymptomatic to symptomatic patients, with the potential for heart failure, supraventricular and ventricular arrhythmias, thromboembolic events, and sudden cardiac death. There is no therapy specific for patients with LVNC. The treatment focuses on the complications of the disease.

Keywords: Left ventricle noncompaction, cardiomyopathy, echocardiography, non compacted myocardium
teries. The process of trabecular compaction in humans starts at the base and progresses toward the apex. Compaction is most pronounced in the left ventricle, and substantial growth and compaction occur throughout postnatal development.

LVNC is hypothesized to be due to early cessation of compaction of trabecular meshwork during embryogenesis. The result is an epicardial layer that is compacted and an endocardial layer with prominent trabeculae and deep intertrabecular recesses that communicate with the left ventricle cavity. Because the apex is the last to undergo compaction, ventricular noncompaction is usually localized toward the apical region.

**ETIOLOGY**

There have been described familial and acquired form of LVNC. The discussion against the developmental hypothesis comes from serial echocardiographic studies where LVNC was not diagnosed on initial echocardiogram but was becoming evident in subsequent examinations. Recent advances in genetics, however, raise the question whether LVNC can also develop postnatally. Some genes have been linked to the development of LVNC: tafazine, β-distrobrevine (DTNA), Cyber/ZASP (LDB3), laminine A/C (LMNA), SCN5A, MYH7 and MYBPC3. Some genes involved in LVNC are also involved in hypertrophic cardiomyopathy and dilated cardiomyopathy (genes that encodes sarcomeric proteins).

There are report of some association between LVNC and congenital cardiac defects. For example, Barth syndrome is a X-linked disorder (G4.5 gene in Xq 28 region) characterised by LVNC, dilated cardiomyopathy, neutropenia and skeletal myopathy.

**HISTOLOGY**

Histologically, LVNC is defined by deep intertrabecular recesses which communicate with the left ventricular cavity. Fibrosis has been described in multiple reports with endomyocardial thickening and subendocardial fibroelastosis. Several reports have observed necrotic myocytes within the prominent trabeculae, but not in the epicardial layer. Those trabeculae are often localized near the apex and papillary muscles are not totally developed.

**PHYSIOPATHOLOGY**

The two layers of myocardium and the trabeculae are vascularized by the coronary arteries, and the intertrabecular recesses are getting blood from the ventricular cavity. In the development of the heart, there arise a mismatch between the myocardial mass and the number of capillaries. In conclusion, there is a hypo perfusion of the endocardial myocardium despite normal epicardial coronary arteries. This amount of ischemia is responsible for the progressive fibrosis that ultimately will depress the systolic function of left ventricle and predispose to ventricular arrhythmias. The excessive trabeculation will compromise the diastolic function of left ventricle, also.

We should permanently consider LVNC a potentially thromboembolic disease, because the blood stagnate in the intertrabecular recesses predisposing to clots formation, that can embolise in the systemic circulation.

**CLINICAL PRESENTATION**

The asymptomatic period is very different, but it is estimated that the mean time from the beginning of symptoms to the diagnosis is about three years.

The triad of heart failure symptoms, arrhythmias and embolic events is the major clinical manifestation in patients with reduced systolic left ventricular function and is comparable in adult and paediatric populations. Various patterns of arrhythmias, ranging from atrial fibrillation (7-26%) to sustained ventricular tachycardia (41%), can be observed. There have been reported cases presenting with atrioventricular block, left bundle branch block and sudden cardiac death. Incidental and familial discovery of LVNC has been associated with high probability of a stable course over several years, whereas patients with symptoms of HF, histories of sustained ventricular tachycardia, or enlarged left atrium have an unstable clinical course and a grave prognosis.

The symptoms can vary widely: atypical chest pain, syncope, systemic and pulmonary embolism. It is important that mortality and morbidity is proportional to the severity of systolic dysfunction of left ventricle.

**ELECTROCARDIOGRAPHY**

LVNC give rise to nonspecific electrocardiography modifications, like:

- ST segment and T wave modification (negative T waves and ST segment depression)
- Left ventricle hypertrophy (amplitude criteria)
- Complete left bundle branch block (21-44%)
- Complete atrioventricular block
- Atrial fibrillation (7-26%)
- Ventricular premature beats
- Ventricular tachycardia (4,2-30%)
- Ventricular fibrillation
- WPW pattern in young patients.

Electrocardiography can be normal in 13% of patients\textsuperscript{12}.

**DIAGNOSTIC CRITERIA**

A ratio of 1.29 between compacted and non-compacted myocardium is considered normal. There are some normal variants, like: hypertrabeculated left ventricle and septomarginal trabecula. The most used and validated method of diagnostic is echocardiography. Several echocardiographic and magnetic resonance imaging definitions for the diagnosis of LVNC have been proposed and used in published studies. There are three sets of echocardiographic criteria (Chin, Jenni and Stollberger) and two sets of magnetic resonance imaging criteria (Peterson and Jacquier) (Table 1). Although all of the proposed definitions attempt to describe the morphology of LVNC, there is variability in these definitions. The lack of a true “gold standard,” such as a reliable genetic marker, makes it difficult to know whose criteria are “best” and ought to be used preferentially.

**Echocardiography.** Chin et al. defined LVNC as a ratio of compacted/compacted + noncompacted myocardium <0.5 at end-diastole (using parasternal short-axis for the apex and apical views for the left ventricle free wall)\textsuperscript{10}.

Jenni el all defined LVNC as ratio of noncompacted/compacted myocardium > 2 measured at end systole (using apical short-axis view)\textsuperscript{13}.

Stollberger defined LVNC as trabeculations (≥ four trabeculae) protruding from the left ventricle wall, located apically to the papillary muscles and visible in one imaging plane\textsuperscript{14}.

Each sets of echocardiographic criterias used have advantages and disadvantages\textsuperscript{15}. Jenni et al. criterias, using end-systolic thickness, were validated against autopsy as well as other structural heart disease. Also with autopsy confirmation, Chin et al. criterias, using end-diastolic measurement, allow for optimal measurement of noncompacted and compacted myocardium in some cases. There are observation that the measurements of the thickness of each layer of the bilayered myocardium are made more precisely during end-diastole, like in Chin’s criterias, than during end-systole, like in Jenni’s criterias. Some observational studies have reported that the thickness of noncompacted myocardium do not change during cardiac cycle unlike compacted myocardium that increases its thickness during systole because its contractile reserve\textsuperscript{5}. According to this data, Jenni’s criteria has higher specificity and lower sensitivity than Chin’s criterias\textsuperscript{27}.

There was poor correlation among the three echocardiographic definitions, with only 30% of patients fulfilling all three criteria\textsuperscript{15}. Those criterias tends to overdiagnose LVNC, because 8% of healthy individuals fulfilled one criteria\textsuperscript{15}. Echocardiography tends to overestimate de prevalence of LVNC in black individuals.

Speckletracking echocardiography (STE) gives promising result in borderline cases, because LVNC affects the left ventricle twist\textsuperscript{16}.

**Echocardiographic pitfalls.** A good echocardiographic exam depend on the experience of the investigator and it is important to have a very good echocardiographic window. The oblique section (frequently the short axis view) generates a lot of inconclusive or false positive results. There are some normal variants that prone to confusion: hypertrabeculated myocardium, septomarginal trabecula, papillary muscles. Frequently, it is very hard to visualize the left ventricle apex and a lot of cases of LVNC localized at the apex are missed\textsuperscript{3}.

**Cardiac magnetic resonance (CMR) imaging.** Peterson et al. and Jacquier et all’s have elaborated some magnetic resonance imaging criterias for defining LVNC (Table 1). CMR has been successfully used to distinguish myocardial trabeculations from global LV mass. A trabeculated LV mass > 20% of the global LV mass is regarded as a sensitive and specific finding for the diagnosis of LVNC\textsuperscript{17}. CMR approaches are evolving and may hold promise for more accurate identification of LVNC.

**Others investigations.** Positron emission tomography (PET), which quantitatively evaluates myocardial blood flow and coronary flow reserve, may be used to assess microcirculatory dysfunction ultimately responsible for the wall motion abnormalities.

Cardiac catheterization is used when there is a cardiac congenital defect in association with LVNC.

The typical features of IVNC have also been observed by ventriculography. After injection of contrast medium, the “loosened” myocardium can be identified. However, a left ventricular angiogram and coronary angiography are usually performed to rule out other concomitant cardiac abnormalities and not for the diagnosis of LVNC.

**DIFFERENTIAL DIAGNOSIS**

The differential diagnosis must be made with:
- Hypertrabeculated myocardium (when there is ≤ 3 trabeculae on the same echocardiographic imagine)
- Apical hypertrophic cardiomyopathy
- Left ventricle hypertrophy
- Hypertensive cardiomyopathy
- Dilated cardiomyopathy
- Myocardial hematomas
- Aberrant tendineae chordae
- Apical cardiac tumors
- Apical clots
- Arrhythmogenic Right Ventricular Dysplasia
- Myocardial/endoocardial fibroelastosis

Differential diagnosis between dilated cardiomyopathy and LVNC can be a challenge in dilated ventricles.

**EVALUATION AND PROGNOSTIC**

There have been identified some risk factors in patients with LVNC, like: age at initial presentation, NYHA class, sustained ventricular arrhythmias, the extent of non compaction, left ventricle end diastolic diameter (Table 2). Despite limitations of the published risk factors for adverse outcomes, they are helpful to guide treatment, including medical therapy and device therapy.

In a larger series of patients, long-term follow up (39 months) showed that 35% died, half of them because of sudden cardiac death, and 12% (four patients) had undergone heart transplantation. The high incidence of both thromboembolic events (24%) and ventricular tachycardia (41%) in that series underscores the poor clinical prognosis for patients with impaired left ventricular function.

**TREATMENT**

There is no therapy specific for patients with LVNC. Treatment for noncompaction of the ventricular myocardium focuses on the 3 major clinical manifestations: heart failure, arrhythmias, and systemic embolic events.

Patients with LVNC that develop systolic or diastolic heart failure should be managed according to the guidelines in use. The beneficial effects of the β-blocker carvedilol on left ventricular function, mass, and neurohormonal dysfunction in an infant with LVNC have been described. When heart failure is progressive, despite maximum medical therapy, device therapy should be considered. Cardiac transplantation has been used for those with refractory congestive heart failure.

**Table 1. Echocardiographic and magnetic resonance imaging diagnostic criterias for LVNC (modified by 3).**

<table>
<thead>
<tr>
<th>ECHOCARDIOGRAPHY</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chin et al.</strong></td>
</tr>
<tr>
<td>• Two-layered structure of the myocardium (epicardial compacted, endocardial non-compacted layer)</td>
</tr>
<tr>
<td>• Compacted/compacted + noncompacted myocardium &lt;0.5 at end-diastole</td>
</tr>
<tr>
<td>• Acquisition of the images: parasternal short-axis view</td>
</tr>
<tr>
<td><strong>Jenni et al.</strong></td>
</tr>
<tr>
<td>• Two-layered structure of the myocardium (epicardial compacted, endocardial non-compacted layer)</td>
</tr>
<tr>
<td>• Noncompacted/Compacted myocardium &gt;2.0 at end-systole</td>
</tr>
<tr>
<td>• Predominant location of the pathology: mid-lateral, mid-inferior, and apex</td>
</tr>
<tr>
<td>• Colour Doppler evidence of deep intertrabecular recesses filled with blood from the left ventricular cavity</td>
</tr>
<tr>
<td>• Absence of coexisting cardiac abnormalities (in the presence of isolated LVNC)</td>
</tr>
<tr>
<td>• Acquisition of the images: short-axis views</td>
</tr>
<tr>
<td><strong>Stöllberger et al.</strong></td>
</tr>
<tr>
<td>• More than three trabeculations protruding from the left ventricular wall, located apically to the papillary muscles and visible in one image plane</td>
</tr>
<tr>
<td>• Trabeculations with the same echogenicity as the myocardium and synchronous movement with ventricular contractions</td>
</tr>
<tr>
<td>• Perfusion of the intertrabecular spaces from the left ventricular cavity</td>
</tr>
<tr>
<td>• Noncompacted/Compacted myocardium &gt;2.0 at end-diastole</td>
</tr>
<tr>
<td>• Acquisition of the images: apical four chamber view; angulation of the transducer and acquisition of pictures in atypical views to obtain the technically best picture quality for differentiation between false chords/aberrant bands and trabeculations</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MAGNETIC RESONANCE IMAGING</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Petersen et al.</strong></td>
</tr>
<tr>
<td>• Noncompacted/Compacted myocardium &gt; 2.3 at end-diastole</td>
</tr>
<tr>
<td><strong>Jacquier et al.</strong></td>
</tr>
<tr>
<td>• Trabeculated left ventricular mass &gt;20% of the global left ventricular mass at end-diastole</td>
</tr>
</tbody>
</table>

**Table 2. Prognostic factors in LVNC (modified by 3).**

<table>
<thead>
<tr>
<th>Clinical predictors</th>
<th>Age at initial presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Echocardiographic parameters</td>
<td>Ratio of non-compacted to compacted layers</td>
</tr>
<tr>
<td></td>
<td>Number of affected segments</td>
</tr>
<tr>
<td></td>
<td>LV end-diastolic diameter</td>
</tr>
<tr>
<td></td>
<td>Abnormal lateral mitral tissue Doppler Ea velocity</td>
</tr>
</tbody>
</table>
Patients with LVNC should be closely evaluated for ventricular arrhythmias. Because of the frequency of ventricular tachycardia and significant risk of sudden cardiac death and systemic embolism, assessment for atrial and ventricular arrhythmias by ambulatory ECG monitoring should be performed annually. Patients with LVNC and sustained ventricular tachycardia or ventricular fibrillation require implantable cardioverter-defibrillator implant. Radiofrequency ablation also may be a consideration. Prophylactic implantable cardioverter-defibrillator implant in the absence of documented hemodynamically significant ventricular tachycardia is currently not recommended. Prevention of embolic complications is an important management goal and remains a matter of debate in these patients. The incidence of thromboembolic complications ranges from 5% to 38%. Because deep intertrabecular recesses with sluggish blood flow aggravate the risk of thrombus formation, it is recommended oral anticoagulation (target INR 2.0–3.0) in patients with impaired systolic function (LV ejection fraction ≤40%), previous history of trombembolism, transient ischemic attack, being aware of the absence of any robust data to support this approach. Anticoagulation therapy, however, must be targeted to the individual patient after careful assessment of the benefit and risks.

There have been used some metabolic cocktails, with somewhat good result in children: B1 and B12 vitamin, Q10 coenzyme and carnitine. This results are explained by the high frequency of the mitochondrial abnormalities in patients with LVNC.

There are no guidelines for exercise prescriptions or restrictions for LVNC in the literature. Even in the most recent review of this subject by Oechslin and Jenni in 2011, no mention is made of the advisability of exercise restriction or prescription. This is a large gap in clinical practice that needs attention through further systematic evaluation of these patients to understand the risk exercise poses to this subset of patients.

FOLLOW UP

It is reasonable to reevaluate the patients biannually. The patients must be put on a waiting list for heart transplantation, especially symptomatic patients. We should not forget the screening of relatives.

CONCLUSION

Knowledge and understanding about aetiology, embryogenesis of the myocardium, genetic background, diagnosis and outcome of LVNC have steadily improved. Non-compaction of the left ventricular myocardium is within a diverse spectrum of myocardial morphologies/cardiomopathies triggered by gene defects/mutations: the causal role of LVNC in the pathogenesis of a distinct cardiomyopathy is questionable.

LVNC results from an arrest of normal ventricular myocardial maturation by heretofore unknown molecular mechanisms. The resulting bilayered ventricular myocardium is prone to LV diastolic and systolic dysfunction, HF, arrhythmias, and thromboembolic complications.

Echocardiography is the current gold standard for diagnosis of this entity. Echocardiographers and clinicians have to be cautioned not to overdiagnose LVNC. Newer imaging approaches and technologies may continue to redefine diagnostic criteria for this unusual and distinct cardiomyopathy.

There is no therapy specific for patients with LVNC. The treatment focuses on the complications of the disease.

Conflict of interests: The authors declare that no conflict of interest exists.

Bibliography

1. Ginghina Carmen, Cardiomiopatii neclasificate, Mic tratat de cardiologie, Editura Academiei Romane, Bucuresti, 2010, pag. 385-387
22. McMurray JJ et al., ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012 Aug;14(8):803-69